What is the flagship drug of Eli Lilly?
•
3 min read
In the first half of 2025, the combined sales of tirzepatide, marketed as Mounjaro and Zepbound, reached over $14.7 billion, solidifying its position as the clear answer to the question, **what is the flagship drug of Eli Lilly?**. The dual GIP/GLP-1 receptor agonist has transformed the treatment landscape for both Type 2 diabetes and obesity.
